NASDAQ:VRNA
Verona Pharma plc Stock News
$15.47
+0.160 (+1.05%)
At Close: Apr 26, 2024
Verona Pharma (NASDAQ:VRNA) Price Target Increased to $23.00 by Analysts at Canaccord Genuity
10:20am, Monday, 15'th Nov 2021 Dakota Financial News
Verona Pharma (NASDAQ:VRNA) had its price target hoisted by Canaccord Genuity from $18.00 to $23.00 in a research report released on Friday, Analyst Price Targets reports. Canaccord Genuity currently has a buy rating on the stock. Other equities analysts also recently issued reports about the stock. HC Wainwright began coverage on shares of Verona Pharma []
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q3 2021 Results - Earnings Call Transcript
02:32pm, Tuesday, 09'th Nov 2021
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q3 2021 Results - Earnings Call Transcript
Verona Pharma Announces November 2021 Investor Conference Participation
03:00am, Monday, 01'st Nov 2021
LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announce
Verona Pharma to Report Third Quarter 2021 Financial Results and Provide Corporate Update
02:00am, Tuesday, 26'th Oct 2021
LONDON and RALEIGH, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announce
Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021
02:00am, Wednesday, 13'th Oct 2021
Bronchodilation demonstrated with pMDI, consistent with DPI and nebulizer formulations Bronchodilation demonstrated with pMDI, consistent with DPI and nebulizer formulations
Verona Pharma Presents Pharmacokinetic Data with Ensifentrine at the European Respiratory Society International Congress 2021
02:00am, Thursday, 02'nd Sep 2021
Results demonstrate co-administration of fluconazole has minimal effect on ensifentrine pharmacokinetics Results demonstrate co-administration of fluconazole has minimal effect on ensifentrine pharmac
Verona Pharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference
02:00am, Tuesday, 31'st Aug 2021
LONDON and RALEIGH, N.C., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announce
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q2 2021 Results - Earnings Call Transcript
10:28am, Saturday, 07'th Aug 2021
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q2 2021 Results - Earnings Call Transcript
Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update
02:00am, Thursday, 05'th Aug 2021
ENHANCE Phase 3 program on track to report top-line data in 2022
Verona Pharma Announces August 2021 Virtual Investor Conference Participation
02:00am, Tuesday, 27'th Jul 2021
LONDON and RALEIGH, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announce
Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update
02:00am, Thursday, 22'nd Jul 2021
LONDON and RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announce
Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO
04:20pm, Sunday, 13'th Jun 2021
Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO
VRNA Stock Price: Over 15% Increase Pre-Market Explanation
08:38am, Thursday, 10'th Jun 2021
The stock price of Verona Pharma PLC (NASDAQ: VRNA) increased by over 15% pre-market. This is why it happened.
Verona Pharma to Present at Jefferies Virtual Healthcare Conference
02:00am, Tuesday, 25'th May 2021
LONDON and RALEIGH, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces
Posters highlight ensifentrine's safety profile and its potential to improve lung function and quality of life irrespective of COPD severity Posters highlight ensifentrine's safety profile and its pot
